Certriad
Generic name: rosuvastatin calcium and fenofibric acid
Treatment for: High Cholesterol, Hypertriglyceridemia, Hyperlipoproteinemia
Abbott and AstraZeneca End License Agreement for the Development of Certriad
ABBOTT PARK, Ill., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Abbott announced today that Abbott and AstraZeneca will discontinue their joint collaboration for the development of Certriad (rosuvastatin / fenofibric acid delayed release) Capsules. The companies reached this decision after careful consideration of the Complete Response Letter received from the U.S. Food and Drug Administration, the resulting regulatory delay and the commercial attractiveness of the product in the U.S. market.
There will be no financial impact to Abbott's ongoing earnings per share in 2010 or 2011 resulting from this action.
About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
SOURCE Abbott
CONTACT: Media, Elizabeth Hoff, +1-847-935-4236, or Financial, Larry Peepo, +1-847-935-6722, both of Abbott
Web Site: http://www.abbott.com
Posted: December 2010
Related articles
- AstraZeneca and Abbott Receive FDA Complete Response Letter on Certriad New Drug Application - March 30, 2010
- Abbott and AstraZeneca Submit New Drug Application to the FDA for Certriad, an Investigational Treatment for Mixed Dyslipidemia - June 4, 2009
Certriad (rosuvastatin calcium and fenofibric acid) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
